Fig. 4From: Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacityFunctional analysis of the hepatocytes derived from WT and hypoimmunogenic hPSCs. A Schematic of the protocol and stages for the hepatic differentiation of hPSCs. B Representative immunofluorescence images of alpha-fetoprotein (AFP) in hepatocytes differentiated from WT and hypoimmunogenic hPSCs. Scale bar, 25 μm. C Bright-field images showing hepatocytes morphology derived from WT and hypoimmunogenic hPSCs. Arrowheads, binucleated hepatocytes. Scale bar, 50 μm. D Representative immunofluorescence images of albumin (ALB) in hepatocytes differentiated from WT and hypoimmunogenic hPSCs. Scale bar, 25 μm. E FACS quantification showing the percentages of ALB+ cells on day 21 hepatic differentiation of WT and hypoimmunogenic hPSCs. Data are represented as mean ± SEM. n.s., no significance, n = 3, Student’s t test. F MLR analysis showing relative proliferation of PBMCs after coculturing with hepatocytes differentiated from WT, B2Mnull, B2MmHLAG, and B2Mm/sHLAG hPSCs. PBMCs cultured only were used as a negative control (NC). Data are presented as mean ± SEM. **p < 0.01, n = 3, Student’s t test. G ELISA quantification showing ALB secretion from WT- and hypoimmunogenic hPSCs-derived hepatocytes. Data are represented as mean ± SEM. n.s., no significance, n = 3, Student’s t test. H ICG uptake and release assay of WT- and hypoimmunogenic hPSCs-derived hepatocytes. Scale bar, 250 μm. I Glycogen synthesis analysis by PAS staining on day 21 hepatic differentiation of WT and hypoimmunogenic hPSCs. Scale bar, 50 μmBack to article page